Empagliflozin Alleviates Renal Ischemia-Reperfusion Injury by Targeting AMPK/NLRP3 Signaling.
BACKGROUND Empagliflozin (EMPA), a sodium glucose cotransporter protein inhibitor, is a widely used hypoglycemic agent in clinical practice and possesses a protective effect against renal ischemia-reperfusion injury (RIRI); however, its underlying protective mechanism remains elusive. Activating NOD-like receptor prote...